UBS raised the firm’s price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to indicate 50-100 patient enrollment forms for Crenessity when the company reports Q4 in early February, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine initiates Phase 3 registrational program for osavampator in MDD
- Closing Bell Movers: Graco down 5% as earnings, guidance miss
- Neurocrine Amends License Agreement with Takeda
- Neurocrine announces amendment to collaboration with Takeda
- No major surprises from Neurocrine presentation, says JPMorgan